Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia

Published:2017-10-04 Issue:2 Volume:124 Page:364-373
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Shen Chan¹²^ORCID,Zhao Bo¹,Liu Lei³,Shih Ya-Chen Tina¹

Affiliation:

1. Department of Health Services Research; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Department of Preventive Medicine; Northwestern University; Chicago Illinois

Funder

Duncan Family Institute

Agency for Healthcare Research and Quality

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference39 articles.

1. Targeted therapy for cancer in the genomic era;Afghahi;Cancer J.,2015

2. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib;Gambacorti-Passerini;J Natl Cancer Inst.,2011

3. Evolution of therapies for chronic myelogenous leukemia;Santos;Cancer J.,2011

4. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors;Jabbour;Cancer.,2011

5. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy;Ibrahim;Blood.,2011

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy;JNCI Cancer Spectrum;2024-08-12

2. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

3. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence;Blood Advances;2023-07-03

4. The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist;Future Oncology;2023-06

5. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions;Journal of Oncology Pharmacy Practice;2023-04-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3